Actavis announced it will acquire Allergan for $66 billion. Marc LoPresti of Lopresti Law Group, and Michael Farr of Farr, Miller & Washington, discuss Pershing Square Bill Ackman's actions.
Actavis is buying Allergan for $66 billion. CNBC's Kate Kelly provides insight to speculation surrounding the benefit of the deal to Pershing Square's Bill Ackman.
Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.
CNBC's Jim Cramer speaks to Brent Saunders, Actavis CEO, and David Pyott, Allergan chairman & CEO, about the growth and R&D budget of the combined companies going forward.
CNBC's David Faber speaks to David Pyott, Allergan chairman & CEO, and Brent Saunders, Actavis CEO about their deal worth roughly $66 billion and what it means for shareholders.
CNBC's David Faber reports Allergan has lost the court battle to prevent Bill Ackman from being able to vote his 9.7 percent stake he owns in the company at the special meeting for shareholders coming in December.
Investor Bill Ackman is in court today over insider trading allegations in the deal between Allergan and Valeant Pharmaceuticals, reports CNBC's Kate Kelly.